Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03746080
Recruitment Status : Recruiting
First Posted : November 19, 2018
Last Update Posted : December 7, 2018
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
Lawrence Recht, Stanford University

Brief Summary:
This phase II trial studies how well whole brain radiation therapy works with standard temozolomide chemo-radiotherapy and plerixafor in treating patients with glioblastoma (brain tumor). Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Plerixafor is a drug that may prevent recurrence of glioblastoma after radiation treatment. Giving whole brain radiation therapy with standard temozolomide chemo-radiotherapy and plerixafor may work better in treating patients with glioblastoma.

Condition or disease Intervention/treatment Phase
Glioblastoma Glioblastoma With Primitive Neuronal Component Gliosarcoma Malignant Glioma Oligodendroglial Component Present Drug: Plerixafor Drug: Temozolomide Radiation: Whole-Brain Radiotherapy (WBRT) Radiation: Radiation Therapy Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To assess the 6 month progression-free survival (PFS) (post initiation of radiation) of continuous infusion plerixafor beginning one week prior to the end of concurrent chemotherapy with temozolomide and a modified radiation regimen that includes a component of whole brain radiation therapy (WBRT) in patients with newly diagnosed glioblastoma (GBM).

SECONDARY OBJECTIVES:

I. To assess the median survival of patients treated with continuous infusion plerixafor/WBRT.

II. To assess the toxicities both short and long term of continuous infusion plerixafor/WBRT.

III. To assess the patterns of failure (in and out of irradiated brain field, out of brain) of continuous infusion plerixafor/WBRT.

OUTLINE:

After completion maximal safe surgical resection, patients undergo radiation therapy for 42 days, initiating whole brain radiation therapy at day 21 (dose 16 of radiation therapy) and receive temozolomide daily on days 1-42. Beginning 7 days before the completion of whole brain radiation therapy, patients receive plerixafor by continuous infusion on days 1-28. Beginning 1 week after completion of plerixafor infusion and 35 days after completion of whole brain radiation therapy, patients receive temozolomide monthly for 6-12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for adverse events for 30 days after the last dose of Plerixafor and then every 12 weeks for 5 years for survival follow-up.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Follow-Up Study to Add Whole Brain Radiotherapy (WBRT) to Standard Temozolomide Chemo-Radiotherapy in Newly Diagnosed Glioblastoma (GBM) Treated With 4 Weeks of Continuous Infusion Plerixafor
Actual Study Start Date : December 4, 2018
Estimated Primary Completion Date : July 11, 2022
Estimated Study Completion Date : January 11, 2027


Arm Intervention/treatment
Experimental: Whole Brain Radiotherapy + Plerixafor +Chemoradiotherapy
After completion maximal safe surgical resection, patients undergo radiation therapy for 42 days, initiating whole brain radiation therapy at day 21 (dose 16 of radiation therapy) and receive temozolomide daily on days 1 to 42. Beginning 7 days before the completion of whole brain radiation therapy, patients receive plerixafor by continuous infusion on days to 1 to 28. Beginning 1 week after completion of plerixafor infusion and 35 days after completion of whole brain radiation therapy, patients receive temozolomide monthly for 6 to 12 courses in the absence of disease progression or unacceptable toxicity.
Drug: Plerixafor
Plerixafor will be administered via infusion at 400 micrograms per kilogram per day for four weeks beginning one week before the end of radiation
Other Names:
  • AMD 3100
  • JM-3100
  • Mozobil
  • SDZ SID 791

Drug: Temozolomide
Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.
Other Names:
  • CCRG-81045
  • Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-
  • M & B 39831
  • M and B 39831
  • Methazolastone
  • RP-46161
  • SCH 52365
  • Temcad
  • Temodal
  • Temodar
  • Temomedac

Radiation: Whole-Brain Radiotherapy (WBRT)
Undergo Whole brain radiotherapy (WBRT) - Radiotherapy consists of 30 Gy in 15 fractions of whole brain radiations
Other Names:
  • WBRT
  • whole-brain radiation therapy
  • whole-brain radiotherapy

Radiation: Radiation Therapy
Radiotherapy consists of 30 Gy in 15 fractions
Other Names:
  • XRT
  • RT




Primary Outcome Measures :
  1. Progression-free survival (PFS) at six months [ Time Frame: 6 months ]
    Progression free survival will be measured at 6 months from diagnosis by biopsy or surgical resection. Simon 2-stage design will be use to assess progression-free survival. Will be computed from start of induction therapy and summarized with Kaplan-Meier estimates.


Secondary Outcome Measures :
  1. Median Survival [ Time Frame: 32 months ]
    Median survival will be assessed at 32 months of subjects who have completed the 28 day Plerixafor infusion. Will be computed from start of induction therapy and summarized with Kaplan-Meier estimates.

  2. Toxicity associated with Plerixafor/WBRT [ Time Frame: 30 days ]
    Incidence of adverse events will be graded and recorded per Common Terminology Criteria for Adverse Events version 5.0. Will assess reported toxicities up until 30 days of treatment. Adverse events and qualifying dose limiting toxicities (DLTs) will be tabulated by cohort, site and severity.

  3. Patterns of treatment failure [ Time Frame: 5 years ]
    Will assess pattern of failure (out-of-field occurrence or occurrence outside of the brain) over time. Local treatment failure is defined as within the 95% isodose region



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have tissue confirmation of high grade (World Health Organization (WHO) grade IV) glioma including but not limited to glioblastoma, gliosarcoma, glioblastoma with oligodendroglial features, glioblastoma with primitive neuroectodermal tumor (PNET) features.
  • The patient must have post-operative contrast enhanced imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) unless only biopsy performed. For patients having biopsy alone, post-operative imaging is not routinely obtained and therefore the preoperative study will serve as baseline.
  • Patient should have surgery (biopsy, partial resection or gross total resection) and no additional anti-cancer therapy except the chemo-radiation as specified in the protocol.
  • Patients must have Karnofsky performance score >= 60.
  • Absolute neutrophil count (ANC) >= 1500 (at time of screening).
  • Platelets >= 100,000 ml (at time of screening).
  • Serum creatinine =< 1.5mg/dl (at time of screening).
  • Creatinine (Cr) clearance should be > 50 mL/min (at time of screening).
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times the upper limit of normal (at time of screening).
  • If female of childbearing potential, negative pregnancy test (at time of screening).
  • The patient or his/her legal representative must have the ability to understand and willingness to sign a written informed consent document.
  • Patient agrees to use an effective method of contraception (hormonal or two barrier methods) while on study and for at least 3 months following the plerixafor infusion.

Exclusion Criteria:

  • Prior or concurrent treatment with Avastin (bevacizumab).
  • Prior exposure to plerixafor.
  • Prior use of other investigational agents to treat the brain tumor.
  • Recent history of myocardial infarct (less than 3 months) or history of active angina.
  • Prior malignancy except for non-melanoma skin cancer and carcinoma in situ (of the cervix or bladder), unless diagnosed and definitively treated more than 3 years prior to 1st dose of investigational drug.
  • Prior sensitivity to plerixafor.
  • Pregnant or patients who are breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03746080


Contacts
Layout table for location contacts
Contact: Hari Priya Yerraballa 6507249363 yhpriya@stanford.edu
Contact: Sophie Bertrand 650-723-4467 sophieb@stanford.edu

Locations
Layout table for location information
United States, California
Stanford Cancer Institute Palo Alto Recruiting
Palo Alto, California, United States, 94304
Contact: Lawrence Recht    650-725-8630    lrecht@stanford.edu   
Principal Investigator: Lawrence Recht         
Sponsors and Collaborators
Lawrence Recht
Sanofi
Investigators
Layout table for investigator information
Principal Investigator: Lawrence Recht Stanford Cancer Institute Palo Alto

Layout table for additonal information
Responsible Party: Lawrence Recht, Professor of Neurology, Stanford University
ClinicalTrials.gov Identifier: NCT03746080     History of Changes
Other Study ID Numbers: IRB-46410
NCI-2018-02159 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
BRN0037 ( Other Identifier: OnCore Number )
IRB-46410 ( Other Identifier: Stanford IRB )
First Posted: November 19, 2018    Key Record Dates
Last Update Posted: December 7, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Glioma
Gliosarcoma
Astrocytoma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Plerixafor octahydrochloride
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents